RCD405 / Respiratorius, Iconovo - LARVOL DELTA

Characterisation of the novel quinoline RCD405: Relaxant effects on cholinergic and histaminergic tone in human bronchi and small airways. (PubMed, Br J Pharmacol) - "RCD405 showed significant potential as a novel bronchodilator drug for the treatment of asthma and COPD through its ability to induce relaxation of hASM. These findings suggest that further investigation of RCD405 is warranted as a possible novel treatment of chronic respiratory disorders."

Journal • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases • TRPV1

Pharmacological characterization of the relaxant effect of RCD405 in isolated human small airways (ERS 2024) - "Aim To pharmacologically characterize the relaxant effect of RCD405 in human small airways.MethodsIsolated human small airways (1 mm diameter) were sub-maximally pre-contracted by carbachol (CCh) and histamine (His) at EC70. Calzetta et al., Br J Pharmacol. 2024 Mar; 181:610-639."

Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Pharmacological characterization of the relaxant effect of RCD405 in isolated human medium bronchi (ERS 2024) - "Aim To pharmacologically characterize the relaxant effect of RCD405 in human medium bronchi.MethodsIsolated human sub-segmental bronchi (4 mm diameter) were sub-maximally pre-contracted by carbachol (CCh) and histamine (His) at EC70. Calzetta et al., Br J Pharmacol. 2024 Mar; 181:610-639."

Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

A novel quinoline with airway relaxant effects and anti-inflammatory properties. (PubMed, Respir Res) - "RCD405 has airway relaxant effects, and it reduces AHR as well as airway inflammation in the models used, suggesting that it could be a clinically relevant compound to treat inflammatory airway diseases. Possible targets of this compound are complexes of mitochondrial oxidative phosphorylation, resulting in decreased metabolic activity of targeted cells as well as through pathways associated to NF-κB. However, further studies are needed to elucidate the mode of action."

Journal • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases • IL13 • IL4 • IL5

Funding received from Swelife for the development of a new treatment for COPD and severe asthma (Cision) - "Arcede Pharma AB announces that a consortium consisting of Arcede Pharma, Iconovo and Lund University has received just over SEK 2 million from Swelife. The project entitled 'RCD405: New treatment paradigm for patients with COPD' receives a total of SEK 2 million to develop a dry powder formulation and an inhalation product based on the inhaler ICOone® for use in clinical phase I studies and to further characterize the mechanism of action of the drug candidate RCD405, which is intended for the treatment of COPD and severe asthma....The project starts in April 2023 and runs until December 2024."

Financing • New P1 trial • Asthma • Chronic Obstructive Pulmonary Disease • Respiratory Diseases

Notice of allowance for patent application regarding RCD405 in the US (Cision) - "Arcede Pharma announces that the patent application for RCD405 has been allowed by a formal notice of allowance from the United States Patent and Trademark Office. The patent relates to new molecules with a certain structure that can be used to treat diseases characterized by airway contractions, e.g. COPD, asthma, inflammation and/or vasoconstriction (American patent application No: 17/255,264; NOVEL BRONCHODILATING HETERO-LINKED AMIDES). After formal fees are paid, the patent will be granted, giving Arcede Pharma market exclusivity in the US at least until 2039. Patents have previously been granted by the European Patent Office (EPO) and also in Japan, South Africa and Canada."

Patent • Asthma • Chronic Obstructive Pulmonary Disease • Pulmonary Disease • Respiratory Diseases

"Notice of allowance for patent application regarding RCD405 in the US https://t.co/97KnDS71VZ" (@CisionNews)

"BioStock: Arcede Pharmas nye rådgivare om marknaden och RCD405 https://t.co/towRmR2o3B" (@CisionNews)

The Japanese Patent Office grants a patent for the RCD405 (Cision) - "Arcede Pharma announces that the Japanese Patent Office intends to grant the patent application for the RESP9000 series which includes RCD405. A formal Notice of Allowance from the Japan Patent Office has been received. The patent relates to new molecules with a certain structure that can be used to treat diseases characterized by airway contractions, e.g. COPD, asthma, inflammation and/or vasoconstriction, e.g. high blood pressure (Japanese Patent Application No: 2020-570529, NOVEL BRONCHODILATING HETERO-LINKED AMIDES). After the formal fees are paid, the patent will be granted, giving Arcede Pharma market exclusivity in Japan until 2039."

Patent • Asthma • Chronic Obstructive Pulmonary Disease • Pulmonary Disease • Respiratory Diseases

"Japanska patentverket beviljar patent för RCD405 https://t.co/5N7OwIisDF" (@CisionNews)

"BioStock: Arcede Pharmas RCD405 vältolererad https://t.co/ToDOUD74gO" (@CisionNews)

"BioStock: Arcede Pharma’s RCD405 well tolerated https://t.co/S92OMM1L4U" (@CisionNews)